Detecting Alzheimer’s Disease Earlier Could Transform Treatment Options
Identifying Alzheimer’s disease at an earlier stage can provide better support and treatment options for patients, while also offering scientists more time to study the disease. Recent research suggests that diagnosis could be accelerated by more than a decade in some cases, thanks to a breakthrough discovery.
An international team of researchers has found that individuals with a genetic predisposition to Alzheimer’s disease may exhibit a particular biomarker in their blood up to 11 years before cognitive symptoms manifest. This biomarker, known as beta-synuclein, can be easily detected through a simple blood test and is indicative of damaged neuronal connections in the brain. The protein’s association with dementia has been increasingly recognized in the scientific community.
Neurologist Patrick Öckl from the German Center for Neurodegenerative Diseases explains, “Blood levels of this protein reflect neuronal damage and can be determined relatively easily. In this, we see a potential biomarker for the early detection of neurodegeneration.”
The research involved analyzing blood samples from 178 individuals enrolled in an Alzheimer’s research database. Participants included both symptomatic and asymptomatic carriers of genetic mutations associated with Alzheimer’s. Statistical analysis revealed higher levels of beta-synuclein in asymptomatic mutation carriers compared to non-carriers, with the highest levels observed in symptomatic carriers, indicating a strong correlation with early dementia-related damage.
While the participants were not monitored longitudinally, the potential to detect this protein could provide over a decade of early warning before symptoms manifest. Beta-synuclein is released when neuronal connections break down, offering insights into the early stages of dementia development.
Markus Otto, a neurologist from University Medicine Halle in Germany, emphasizes, “After the onset of symptoms, the more severe the cognitive impairment, the higher the beta-synuclein level in the blood. Thus, this biomarker reflects pathological changes in both the pre-symptomatic and symptomatic stages.”
Besides early diagnosis, monitoring beta-synuclein levels may aid in tracking Alzheimer’s progression, evaluating treatment efficacy, and assessing brain damage from other conditions like stroke. Early detection is crucial for optimizing the benefits of emerging treatments that can delay symptom onset significantly.
Öckl underscores the importance of advancements in diagnostics, stating, “At the moment, Alzheimer’s is usually diagnosed quite late. Thus, we need advances in diagnostics. Otherwise, we won’t be able to tap the full potential of these new drugs.” Testing beta-synuclein levels in high-risk individuals could unlock the potential of these treatment breakthroughs.
The study has been published in Alzheimer’s & Dementia.
